<DOC>
	<DOC>NCT02362503</DOC>
	<brief_summary>The purpose of this study is to determine whether the BMS Attachment Inhibitor (BMS-663068) is effective in the treatment of heavily treatment experienced HIV-1 patients with multi-drug resistance.</brief_summary>
	<brief_title>Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients</brief_title>
	<detailed_description />
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Men and nonpregnant women with chronic HIV1 infection Antiretroviralexperienced with documented historical or baseline resistance, intolerability, and/or contraindications to antiretrovirals in at least three classes Failing current antiretroviral regimen with a confirmed plasma HIV1 RNA ≥ 400 c/mL (first value from Investigator, second from Screening labs) Must have ≤ 2 classes with at least 1 but no more than 2 fullyactive antiretrovirals remaining which can be effectively combined to form a viable new regimen, based on current and/or documented historical resistance testing and tolerability and safety Able to receive ≥ 1 fully active approved antiretroviral as part of the OBT from Day 9 onwards in the Randomized Cohort Subjects without any remaining fully active approved antiretroviral may be enrolled in the NonRandomized Cohort Chronic untreated Hepatitis B virus (HBV) (however, patients with chronic treated HBV are eligible) HIV2 infection Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 7 x ULN Alkaline Phosphatase &gt; 5 x ULN Bilirubin ≥ 1.5 x Upper limit of normal (ULN) (unless subject is currently on atazanavir and has predominantly unconjugated hyperbilirubinemia)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>